Abstract Number: 282 • 2014 ACR/ARHP Annual Meeting
Pharmacovigilance in Juvenile Idiopathic Arthritis Patients (PHARMACHILD) Treated with Biologic Agents and/or Methotrexate. Consolidated Baseline Characteristics from Pharmachild and Other National Registries
Background/Purpose The availability of methotrexate (MTX) and biological agents has provided a major change in the treatment of children with juvenile idiopathic arthritis (JIA). However,…Abstract Number: 281 • 2014 ACR/ARHP Annual Meeting
Retrospective Review of Immobilization Vs. Immediate Resumption of Activity in Patients with Oligoarticular Juvenile Idiopathic Arthritis and Corticosteroid Knee Injections
Background/Purpose Intraarticular corticosteroid injection (IACI) is one of the most common treatment modalities in oligoarticular Juvenile Idiopathic Arthritis (JIA). There is widespread use of IACI…Abstract Number: 280 • 2014 ACR/ARHP Annual Meeting
Biologic Treatment of Adult Patients with Juvenile Idiopathic Arthritis Followed in the National Registry
Background/Purpose To analyze the efficacy and safety of biologic agents in adult patients with juvenile idiopathic arthritis (JIA).Methods ATTRA is the Czech national registry of…Abstract Number: 279 • 2014 ACR/ARHP Annual Meeting
Focus on Patient Reported Outcomes in Juvenile Idiopathic Arthritis: There Is Room to Improve Care
Background/Purpose National registry cross-sectional data show significant differences in patient-reported outcomes (PROs) across juvenile idiopathic arthritis (JIA) subtypes. This study aimed to assess predictors of…Abstract Number: 278 • 2014 ACR/ARHP Annual Meeting
Is It Worth Allowing the Presence of Morning Stiffness in the Definition of Inactive Disease in Juvenile Idiopathic Arthritis?
Background/Purpose Morning stiffness is a major symptom of juvenile idiopathic arthritis (JIA) and it is usually associated with active disease. However, it is common view…Abstract Number: 297 • 2014 ACR/ARHP Annual Meeting
S100 Proteins in Oligoarticular Juvenile Idiopathic Arthritis
Background/Purpose There is a lack of reliable biomarkers that correlate with active juvenile idiopathic arthritis (JIA). The S100A8/A9 heterodimer (calprotectin) and S100A12 are proinflammatory…Abstract Number: 296 • 2014 ACR/ARHP Annual Meeting
Countermeasures Against Methotrexate Intolerance in Juvenile Idiopathic Arthritis Instituted By Parents Show No Effect
Background/Purpose: Methotrexate (MTX) is the mainstay treatment in the therapy of children with juvenile idiopathic arthritis (JIA) and can lead to prolonged remission and improved…Abstract Number: 295 • 2014 ACR/ARHP Annual Meeting
Intra-Articular Corticosteroid Injections in Juvenile Idiopathic Arthritis: Results from a UK Prospective Collaborative Study
Background/Purpose Intra-articular corticosteroid injections (IACI) are a standard treatment in juvenile idiopathic arthritis (JIA). This study assessed response to IACI in a large prospective cohort…Abstract Number: 294 • 2014 ACR/ARHP Annual Meeting
Long-Term Pharmacokinetics of Body Surface Area-Adjusted Doses of Golimumab Following Repeated Subcutaneous Administrations in Pediatric Patients with Polyarticular Juvenile Idiopathic Arthritis
Background/Purpose: To assess the pharmacokinetics (PK) and PK-efficacy correlations of body surface area (BSA)-adjusted dosing of 30 mg/m2 golimumab administered subcutaneously (SC) every 4 weeks…Abstract Number: 293 • 2014 ACR/ARHP Annual Meeting
Long Term Functional Outcome and Quality of Life of Patients with Refractory Juvenile Idiopathic Arthritis Treated with Etanercept: Results of the Dutch Arthritis and Biologicals in Children Register
Background/Purpose: Juvenile idiopathic arthritis patients refractory to methotrexate are eligible for treatment with biologic agents. A longitudinal sub-analysis (n=53) of the Dutch Arthritis and Biologicals…Abstract Number: 292 • 2014 ACR/ARHP Annual Meeting
Flares in Children with JIA: Results from the Reacch-out Cohort
Background/Purpose: Disease flares are a concern to patients with JIA, their parents, and caregivers alike; but little is known of disease manifestations during a…Abstract Number: 291 • 2014 ACR/ARHP Annual Meeting
Development of a Serious Game Designed for Children with Juvenile Idiopathic Arthritis
Background/Purpose Juvenile Idiopathic Arthritis (JIA) is the most common chronic paediatric rheumatic disease and cause of physical and psychological disability, with family and school consequences.…Abstract Number: 290 • 2014 ACR/ARHP Annual Meeting
Patterns of Active Joint Involvement in JIA
Background/Purpose: JIA encompasses a set of heterogeneous diseases with chronic joint inflammation. Although the ILAR criteria consider joint counts, they do not reflect specific joint…Abstract Number: 289 • 2014 ACR/ARHP Annual Meeting
Patient-Reported Outcomes in Children with Moderately to Severely Active Polyarticular or Polyarticular-Course Juvenile Idiopathic Arthritis Who Are Prescribed and Treated with Adalimumab
Background/Purpose: Juvenile idiopathic arthritis (JIA) is one of the most common rheumatic diseases of childhood and adolescents, and improvement in health-related quality of life and…Abstract Number: 258 • 2014 ACR/ARHP Annual Meeting
Pain Characteristics Among Patients with Rheumatoid Arthritis in the Context of Patient-Physician Discordance in Disease Activity Assessments
Background/Purpose Healthcare must be patient-centered to achieve optimal outcomes and quality of life. From this perspective, it is significant that patients with rheumatoid arthritis (RA)…
ACR Meeting Abstracts